Skip to main content

Tenpoint Therapeutics to Participate in Upcoming Investor Conferences and Medical Meetings

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced participation in upcoming investor conferences.

  • Morgan Stanley 24th Annual Global Healthcare Conference (New York, NY), September 14. Management will host 1x1 meetings.
  • Citizens Private Ophthalmology Summit (Virtual), September 17. Henric Bjarke, CEO, will present in a fireside discussion at 3:00 p.m. ET on September 17, and management will host 1x1 meetings.

Additionally, Tenpoint Therapeutics will participate in two upcoming medical meetings.

  • Academy 2026 Anaheim presented by the American Academy of Optometry (Anaheim, CA), September 30 – October 3. Academy 2026 Anaheim offers an opportunity to explore the latest advancements in optometry with more than 150 industry-leading exhibitors, innovative papers and posters, and networking opportunities. Visit Tenpoint Therapeutics at Booth 965.
  • The American Academy of Ophthalmology Annual Meeting 2026 (New Orleans, FL), October 9 – 12. This conference brings leaders in the profession together with physicians from across the world for a premier educational experience. Visit Tenpoint Therapeutics at Booth 1955.

To request a meeting with the Tenpoint Therapeutics team, please contact the Morgan Stanley and Citizens conference representatives or contact the Company’s investor relations team at tenpoint@gilmartinir.com.

About Tenpoint Therapeutics

Tenpoint Therapeutics, Ltd. is a global commercial ophthalmic pharmaceutical company focused on the commercialization of YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, the first and only dual-agent eye drop for the treatment of presbyopia, a condition that affects nearly 128 million people in the U.S. and approximately 2 billion people globally.1,2 By understanding real-world needs and partnering with eye care professionals, Tenpoint is working to bring innovation to the aging eye.

To learn more, visit tenpointtherapeutics.com and connect on LinkedIn.

____________________

1 American Optometric Association Health Policy Institute. New Approaches to Presbyopia. 2023. Accessed November 5, 2025. Available at https://www.aoa.org/AOA/Documents/Advocacy/HPI/presbyopia%20brief%20HPI%20Final.pdf.

2 National Eye Institute. Presbyopia. National Eye Institute. December 4, 2024. https://www.nei.nih.gov/learn-about-eye-health/eyeconditions-and-diseases/presbyopia. Accessed January 7, 2026.

 

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  266.93
+7.63 (2.94%)
AAPL  350.69
+8.32 (2.43%)
AMD  508.58
+59.54 (13.26%)
BAC  50.55
+1.13 (2.29%)
GOOG  286.01
+2.08 (0.73%)
META  641.37
+31.22 (5.12%)
MSFT  545.18
+14.57 (2.75%)
NVDA  178.67
-7.97 (-4.27%)
ORCL  119.79
+3.69 (3.18%)
TSLA  378.05
+19.83 (5.54%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.